[Skip to Navigation]
Invited Commentary
Mar 12, 2012

Dabigatran: Do We Have Sufficient Data?Comment on “Dabigatran Association With Higher Risk of Acute Coronary Events”

Author Affiliations

Author Affiliations: The Jerusalem Institute of Aging Research, Department of Geriatrics and Rehabilitation, Hadassah-Hebrew University Medical Center, Mount Scopus, Jerusalem, Israel; and Hebrew University-Hadassah Medical School, Jerusalem, Israel.

Arch Intern Med. 2012;172(5):403-404. doi:10.1001/archinternmed.2011.1721

Dabigatran is certainly in the news at the moment. A PubMed search identified more than 500 publications—with 307 since the start of 2011 as well as a large direct-to-consumer advertising campaign—for this new direct thrombin inhibitor. Changes in anticoagulation therapy seem both likely and imminent.

The explosion of literature on dabigatran draws heavily from the 7 RCTs included in the meta-analysis of Uchino and Hernandez.1 Dabigatran is the primary contender among several to have reached the finish line of phase 3 trials largely unscathed and has gained approval both in the United States and Europe for prophylaxis of VTE and stroke in patients with nonvalvular AF.

Add or change institution